IMMUNOVANT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.39 USD | -3.86% |
|
-12.30% | -39.73% |
| May. 30 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
| May. 29 | Immunovant Q4 Loss Widens -- Shares Fall After-Hours | MT |
Presentation Operator MessageOperator (Operator)Good morning. My name is Sherry, and I will se...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Gravesâ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
25.39
USD
Average target price
50.43
USD
Spread / Average Target
+98.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.73% | 3.71B | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Transcript : Immunovant, Inc. - Special Call
